IP Library › Granted Patent US 12,527,795
Granted Patent B2
US 12,527,795 · App. 17/275,180 · Granted Jan 20, 2026

Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith

Inventors: Peter Olson (San Diego, CA); Ruth Wei Aranda (San Diego, CA); James Gail Christensen (San Diego, CA); Lars Daniel Engstrom (Carlsbad, CA); Jill Hallin (San Diego, CA)
Assignee: Mirati Therapeutics, Inc.
A61K31/519A61K31/436A61K31/4745A61K31/5377A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,527,795
App. No.
17/275,180
Filed
Mar 10, 2021
Granted
Jan 20, 2026
Kind
B2
Art Unit
1627
USPC
514/234.2
Abstract

The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a mTOR inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

Claims (55)

1 . A pharmaceutical composition, comprising a therapeutically effective amount of the combination of a mTOR inhibitor selected from the group consisting of everolimus, rapamycin, zoatarolimus, ridaforolimus, sapanisertib, Torin-1, dacotlisib, BEZ235, buparlisib, GDC-0941, GDC-0349, VS-5584 and vistusertib, and a KRAS G12C inhibitor of formula

or a pharmaceutically acceptable salt thereof: and a pharmaceutically acceptable excipient.

2 . A kit comprising: a) a pharmaceutical composition comprising a mTOR inhibitor selected from the group consisting of everolimus, rapamycin, zotarolimus, ridaforolimus, sapanisertib, Torin-1, dactolisib, BEZ235, buparlisib, GDC-0941, GDC-0349, VS-5584 and vistusertib; and b) a pharmaceutical composition comprising a KRAS G12C inhibitor of formula

or a pharmaceutically acceptable salt thereof for treating cancer in a subject.

3 . A kit comprising the pharmaceutical composition of claim 1 for treating KRAS G12C-associated cancer in a subject.

4 . A method for inhibiting KRAS G12C activity in a cancer cell, comprising contacting the cell in which inhibition of KRAS G12C activity is desired with an effective amount of a mTOR inhibitor selected from the group consisting of everolimus, rapamycin, zotarolimus, ridaforolimus, sapanisertib, Torin-1, dactolisib, BEZ235, buparlisib, GDC-0941, GDC-0349, VS-5584 and vistusertib, and a KRAS G12C inhibitor of formula

or a pharmaceutically acceptable salt thereof,

wherein the mTOR inhibitor synergistically increases the sensitivity of the cancer cells to the KRAS G12C inhibitor.

5 . A method of treating KRAS G12C-associated cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a mTOR inhibitor selected from the group consisting of everolimus, rapamycin, zotarolimus, ridaforolimus, sapanisertib, Torin-1, dactolisib, BEZ235, buparlisib, GDC-0941, GDC-0349, VS-5584 and vistusertib, and a KRAS G12C inhibitor of formula

or a pharmaceutically acceptable salt thereof.

6 . The method according to claim 5 , wherein the therapeutically effective amount of the KRAS G12C inhibitor compound is between about 0.01 to 100 mg/kg per day.

7 . The method according to claim 5 , wherein the cancer is selected from the group consisting of

Cardiac cancer,

Lung cancer,

Gastrointestinal cancer,

Genitourinary tract cancer,

Liver cancer,

Biliary tract cancer,

Nervous system cancer,

Gynecological cancer,

Hematologic cancer and

Skin cancer.

8 . The method of claim 5 , wherein the KRAS G12C-associated cancer is non-small cell lung cancer.

9 . The method according to claim 5 , wherein said cancer is a sarcoma selected from angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma, myxoma, rhabdomyoma, fibroma, lipoma and teratoma.

10 . The method according to claim 5 , wherein said KRAS G12C-associated cancer selected from squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma and mesothelioma.

11 . The method according to claim 5 , wherein said cancer is a gastrointestinal cancer selected from esophagus cancer, squamous cell carcinoma, adenocarcinoma, and leiomyosarcoma.

12 . The method according to claim 5 , wherein said cancer is selected from leiomyosarcoma, pancreatic cancer, ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma.

13 . The method according to claim 5 , wherein said cancer is small bowel cancer selected from adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma.

14 . The method according to claim 5 , wherein said cancer is large bowel cancer selected from adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma.

15 . The method according to claim 5 , wherein said cancer is genitourinary tract cancer, kidney cancer, adenocarcinoma or nephroblastoma.

16 . The method according to claim 5 , wherein said cancer is genitourinary tract bladder or urethra cancer selected from squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma.

17 . The method according to claim 5 , wherein said cancer is prostate cancer selected from adenocarcinoma and sarcoma.

18 . The method according to claim 5 , wherein said cancer is testicular cancer selected from seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors and lipoma.

19 . The method according to claim 5 , wherein said cancer is liver cancer.

20 . The method according to claim 19 , wherein said liver cancer is selected from hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.

21 . The method according to claim 5 , wherein said cancer is selected from gallbladder carcinoma, ampullary carcinoma, cholangiocarcinoma, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, reticulum cell sarcoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, osteocartilaginous exostoses, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.

22 . The method according to claim 5 , wherein said cancer is selected from meningioma, meningiosarcoma, gliomatosis, astrocytoma, medulloblastoma, glioma, ependymoma, germinoma, pinealoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors, spinal cord neurofibroma, meningioma, glioma, and sarcoma.

23 . The method according to claim 5 , wherein said cancer is selected from uterine cancer, endometrial carcinoma, serous cystadenocarcinoma, mucinous cystadenocarcinoma, and unclassified carcinoma, granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, and malignant teratoma, vulva cancer, squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma, vagina cancer, squamous cell carcinoma, botryoid sarcoma, embryonal rhabdomyosarcoma, and fallopian tube cancer.

24 . The method according to claim 5 , wherein said cancer is selected from myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome, Hodgkin's disease, non-Hodgkin's lymphoma.

25 . The method according to claim 5 , wherein said cancer is selected from malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, adrenal gland cancer and neuroblastoma.

26 . A method of treating KRAS G12C-associated cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a mTOR inhibitor selected from the group consisting of everolimus, rapamycin, zotarolimus, ridaforolimus, sapanisertib, Torin-1, dactolisib, BEZ235, buparlisib, GDC-0941, GDC-0349, VS-5584 and vistusertib; and a KRAS G12C inhibitor of formula

or a pharmaceutically acceptable salt thereof; wherein said KRAS G12C-associated cancer is selected from non-small cell lung cancer, colorectal cancer, pancreatic cancer and endometrial cancer.

27 . The method according to claim 26 , wherein said mTOR inhibitor is everolimus.

28 . The method according to claim 26 , wherein said mTOR inhibitor is rapamycin.

29 . The method according to claim 26 , wherein said mTOR inhibitor is zotarolimus.

30 . The method according to claim 26 , wherein said mTOR inhibitor is ridaforolimus.

31 . The method according to claim 26 , wherein said mTOR inhibitor is sapanisertib.

32 . The method according to claim 26 , wherein said mTOR inhibitor is Torin-1.

33 . The method according to claim 26 , wherein said mTOR inhibitor is dactolisib.

34 . The method according to claim 26 , wherein said mTOR inhibitor is buparlisib.

35 . The method according to claim 26 , wherein said mTOR inhibitor is BEZ235.

36 . The method according to claim 26 , wherein said mTOR inhibitor is GDC-0941.

37 . The method according to claim 26 , wherein said mTOR inhibitor is vistusertib.

38 . The method according to claim 26 , wherein said mTOR inhibitor GDC-0349.

39 . The method according to claim 26 , wherein said mTOR inhibitor VS-5584.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2022
From: OLSON, PETER; ARANDA, RUTH WEI; CHRISTENSEN, JAMES GAIL; ENGSTROM, LARS; HALLIN, JILL
To: MIRATI THERAPEUTICS, INC.
Reel/Frame 058637/0801 →
Continuity (2)
Provisional Application 62729228 · Sep 10, 2018
Related Publication 20220040182A1 · Feb 10, 2022
References Cited (362)
US 8163763B2 · Bergeron et al. · 2012 [cited by applicant]
US 8426401B2 · Bian et al. · 2013 [cited by applicant]
US 9562019B2 · Djaballah et al. · 2017 [cited by applicant]
US 9840516B2 · Li et al. · 2017 [cited by applicant]
US 10125134B2 · Blake · 2018 [cited by examiner]
US 20030191143A1 · Pitts et al. · 2003 [cited by applicant]
US 20100081654A1 · Stockwell et al. · 2010 [cited by applicant]
US 20110269244A1 · Petter et al. · 2011 [cited by applicant]
US 20130029978A1 · Kamino et al. · 2013 [cited by applicant]
US 20140288045A1 · Ren et al. · 2014 [cited by applicant]
US 20150175558A1 · Stockwell et al. · 2015 [cited by applicant]
US 20150239900A1 · Li et al. · 2015 [cited by applicant]
US 20160031898A1 · Ren et al. · 2016 [cited by applicant]
US 20160108019A1 · Li et al. · 2016 [cited by applicant]
US 20160166571A1 · Janes et al. · 2016 [cited by applicant]
US 20160229836A1 · Stockwell et al. · 2016 [cited by applicant]
US 20160264627A1 · Henning et al. · 2016 [cited by applicant]
US 20160297774A1 · Li et al. · 2016 [cited by applicant]
US 20170022184A1 · Li et al. · 2017 [cited by applicant]
US 20170115303A1 · Cravatt et al. · 2017 [cited by applicant]
US 20170190672A1 · Mani et al. · 2017 [cited by applicant]
US 20170197945A1 · Li et al. · 2017 [cited by applicant]
US 20180015087A1 · Liu et al. · 2018 [cited by applicant]
US 20180118757A1 · Li et al. · 2018 [cited by applicant]
US 20180118761A1 · Sebti et al. · 2018 [cited by applicant]
US 20180127396A1 · Li et al. · 2018 [cited by applicant]
US 20180141927A1 · Li et al. · 2018 [cited by applicant]
US 20180155348A1 · Li et al. · 2018 [cited by applicant]
US 20180162812A1 · Ren et al. · 2018 [cited by applicant]
US 20180177767A1 · Lanman et al. · 2018 [cited by applicant]
US 20180194748A1 · Li et al. · 2018 [cited by applicant]
US 20180201610A1 · Tao et al. · 2018 [cited by applicant]
US 20180273515A1 · Li et al. · 2018 [cited by applicant]
US 20180273523A1 · Li et al. · 2018 [cited by applicant]
US 20180273577A1 · Revenko et al. · 2018 [cited by applicant]
US 20180282307A1 · Li et al. · 2018 [cited by applicant]
US 20180282308A1 · Li et al. · 2018 [cited by applicant]
US 20180289683A1 · McCormick et al. · 2018 [cited by applicant]
US 20200262837A1 · Marx et al. · 2020 [cited by applicant]
US 20200399297A1 · Campbell et al. · 2020 [cited by applicant]
WO 02053558A1 · 2002 [cited by applicant]
WO 02087513A2 · 2002 [cited by applicant]
WO 2007146122A2 · 2007 [cited by applicant]
WO 2008009078A2 · 2008 [cited by applicant]
WO 2009047255A1 · 2009 [cited by applicant]
WO 2010014939A1 · 2010 [cited by applicant]
WO 2010120996A1 · 2010 [cited by applicant]
WO 2013155223A1 · 2013 [cited by applicant]
WO 2014143659A1 · 2014 [cited by applicant]
WO 2014152588A1 · 2014 [cited by applicant]
WO 2016049568A1 · 2015 [cited by applicant]
WO 2015054572A1 · 2015 [cited by applicant]
WO 2016025650A1 · 2016 [cited by applicant]
WO 2016044772A1 · 2016 [cited by applicant]
WO 2016049565A1 · 2016 [cited by applicant]
WO 2016164675A1 · 2016 [cited by applicant]
WO 2016168540A1 · 2016 [cited by applicant]
WO 2017058728A1 · 2017 [cited by applicant]
WO 2017058768A1 · 2017 [cited by applicant]
WO 2017058792A1 · 2017 [cited by applicant]
WO 2017058805A1 · 2017 [cited by applicant]
WO 2017058807A1 · 2017 [cited by applicant]
WO 2017058902A1 · 2017 [cited by applicant]
WO 2017058915A1 · 2017 [cited by applicant]
WO 2017070256A2 · 2017 [cited by applicant]
WO 2017079864A1 · 2017 [cited by applicant]
WO 2017080980A1 · 2017 [cited by applicant]
WO 2017087528A1 · 2017 [cited by applicant]
WO 2017100546A1 · 2017 [cited by applicant]
WO 2017201161A1 · 2017 [cited by applicant]
WO 2018064510A1 · 2018 [cited by applicant]
WO 2018068017A1 · 2018 [cited by applicant]
WO 2018102452A2 · 2018 [cited by applicant]
WO 2018102453A1 · 2018 [cited by applicant]
WO 2018112420A1 · 2018 [cited by applicant]
WO 2018115380A1 · 2018 [cited by applicant]
WO 2018119183A2 · 2018 [cited by applicant]
WO 2018140512A1 · 2018 [cited by applicant]
WO 2018140513A1 · 2018 [cited by applicant]
WO 2018140514A1 · 2018 [cited by applicant]
WO 2018140598A1 · 2018 [cited by applicant]
WO 2018140599A1 · 2018 [cited by applicant]
WO 2018140600A1 · 2018 [cited by applicant]
WO 2018143315A1 · 2018 [cited by applicant]
WO 2018195439A2 · 2018 [cited by applicant]
WO 2019051291A1 · 2019 [cited by applicant]
WO 202063594 · 2020 [cited by applicant]
WO 202098488 · 2020 [cited by applicant]
WO 202027202 · 2020 [cited by applicant]
WO 2020163598 · 2020 [cited by applicant]
WO 2020165670 · 2020 [cited by applicant]
WO 2020169838 · 2020 [cited by applicant]
WO 2020171499 · 2020 [cited by applicant]
WO 2020172332 · 2020 [cited by applicant]
WO 2020176693 · 2020 [cited by applicant]
WO 2020176963 · 2020 [cited by applicant]
WO 2020177629 · 2020 [cited by applicant]
WO 2020178282 · 2020 [cited by applicant]
WO 2020181142 · 2020 [cited by applicant]
WO 2020198125 · 2020 [cited by applicant]
WO 2020204359 · 2020 [cited by applicant]
WO 2020205473 · 2020 [cited by applicant]
WO 2020205486 · 2020 [cited by applicant]
WO 2020212895 · 2020 [cited by applicant]
WO 2020214537 · 2020 [cited by applicant]
WO 2020221239 · 2020 [cited by applicant]
WO 2020230028 · 2020 [cited by applicant]
WO 2020230091 · 2020 [cited by applicant]
WO 2020231806 · 2020 [cited by applicant]
WO 2020231808 · 2020 [cited by applicant]
WO 2020232130 · 2020 [cited by applicant]
WO 2020233592 · 2020 [cited by applicant]
WO 2020234103 · 2020 [cited by applicant]
WO 2020236940 · 2020 [cited by applicant]
WO 2020236947 · 2020 [cited by applicant]
WO 2020236948 · 2020 [cited by applicant]
WO 2020247914 · 2020 [cited by applicant]
WO 2020252336 · 2020 [cited by applicant]
WO 2020252353 · 2020 [cited by applicant]
WO 2021000885 · 2021 [cited by applicant]
WO 2021023154 · 2021 [cited by applicant]
WO 2021023247 · 2021 [cited by applicant]
WO 2021027911 · 2021 [cited by applicant]
WO 2021027943 · 2021 [cited by applicant]
WO 2021031952 · 2021 [cited by applicant]
WO 2021034992 · 2021 [cited by applicant]
WO 2021037018 · 2021 [cited by applicant]
WO 2021041671 · 2021 [cited by applicant]
WO 2021043322 · 2021 [cited by applicant]
WO 2021045279 · 2021 [cited by applicant]
WO 2021050732 · 2021 [cited by applicant]
WO 2021051034 · 2021 [cited by applicant]
WO 2021052499 · 2021 [cited by applicant]
WO 2021055728 · 2021 [cited by applicant]
WO 2021057832 · 2021 [cited by applicant]
WO 2021058018 · 2021 [cited by applicant]
WO 2021061515 · 2021 [cited by applicant]
WO 2021061749 · 2021 [cited by applicant]
WO 2021063346 · 2021 [cited by applicant]
WO 2021068898 · 2021 [cited by applicant]
WO 2021075147 · 2021 [cited by applicant]
WO 2021076655 · 2021 [cited by applicant]
WO 2021078285 · 2021 [cited by applicant]
WO 2021078312 · 2021 [cited by applicant]
WO 2021080359 · 2021 [cited by applicant]
WO 2021081212 · 2021 [cited by applicant]
WO 2021083167 · 2021 [cited by applicant]
WO 2021084765 · 2021 [cited by applicant]
WO 2021085653 · 2021 [cited by applicant]
WO 2021086833 · 2021 [cited by applicant]
WO 2021088458 · 2021 [cited by applicant]
WO 2021088938 · 2021 [cited by applicant]
WO 2021091956 · 2021 [cited by applicant]
WO 2021091967 · 2021 [cited by applicant]
WO 2021091982 · 2021 [cited by applicant]
WO 2021093758A1 · 2021 [cited by applicant]
WO 2021104431A1 · 2021 [cited by applicant]
WO 2021106230A1 · 2021 [cited by applicant]
WO 2021106231A1 · 2021 [cited by applicant]
WO 2021107160A1 · 2021 [cited by applicant]
WO 2021108683A1 · 2021 [cited by applicant]
WO 2021109737A1 · 2021 [cited by applicant]
WO 2021113595A1 · 2021 [cited by applicant]
WO 2021120045A1 · 2021 [cited by applicant]
WO 2021121330A1 · 2021 [cited by applicant]
WO 2021121367A1 · 2021 [cited by applicant]
WO 2021121371A1 · 2021 [cited by applicant]
WO 2021121397A1 · 2021 [cited by applicant]
WO 2021126120A1 · 2021 [cited by applicant]
WO 2021126799A1 · 2021 [cited by applicant]
WO 2021127404A1 · 2021 [cited by applicant]
WO 2021129820A1 · 2021 [cited by applicant]
WO 2021129824A1 · 2021 [cited by applicant]
WO 2021139678A1 · 2021 [cited by applicant]
WO 2021139748A1 · 2021 [cited by applicant]
WO 2021141628A1 · 2021 [cited by applicant]
WO 2021142252A1 · 2021 [cited by applicant]
WO 2021143693A1 · 2021 [cited by applicant]
WO 2021145520A1 · 2021 [cited by applicant]
WO 2021145521A1 · 2021 [cited by applicant]
WO 2021147965A1 · 2021 [cited by applicant]
WO 2021147967A1 · 2021 [cited by applicant]
WO 2021150613A1 · 2021 [cited by applicant]
WO 2021152149A1 · 2021 [cited by applicant]
WO 2021168193A1 · 2021 [cited by applicant]
WO 2021169963A1 · 2021 [cited by applicant]
WO 2021169990A1 · 2021 [cited by applicant]
WO 2021173923A1 · 2021 [cited by applicant]
WO 2021175199A1 · 2021 [cited by applicant]
WO 2021177721A1 · 2021 [cited by applicant]
WO 2021178740A2 · 2021 [cited by applicant]
WO 2021178741A1 · 2021 [cited by applicant]
WO 2021180181A1 · 2021 [cited by applicant]
WO 2021185233A1 · 2021 [cited by applicant]
WO 2021190467A2 · 2021 [cited by applicant]
WO 2021197499A1 · 2021 [cited by applicant]
WO 2021203768A1 · 2021 [cited by applicant]
WO 2021207172A1 · 2021 [cited by applicant]
WO 2021211864A1 · 2021 [cited by applicant]
WO 2021215544A1 · 2021 [cited by applicant]
WO 2021216770A1 · 2021 [cited by applicant]
WO 2021217019A1 · 2021 [cited by applicant]
WO 2021090855A1 · 2021 [cited by applicant]
WO 2021218110A1 · 2021 [cited by applicant]
WO 2021219072A1 · 2021 [cited by applicant]
WO 2021219090A2 · 2021 [cited by applicant]
WO 2021219091A1 · 2021 [cited by applicant]
WO 2021228161A1 · 2021 [cited by applicant]
WO 2021231526A1 · 2021 [cited by applicant]
WO 2021236475A1 · 2021 [cited by applicant]
WO 2021239058A1 · 2021 [cited by applicant]
WO 2021243280A1 · 2021 [cited by applicant]
WO 2021244603A1 · 2021 [cited by applicant]
WO 2021245051A1 · 2021 [cited by applicant]
WO 2021245055A1 · 2021 [cited by applicant]
WO 2021245499A1 · 2021 [cited by applicant]
WO 2021248079A1 · 2021 [cited by applicant]
WO 2021248082A1 · 2021 [cited by applicant]
WO 2021248083A1 · 2021 [cited by applicant]
WO 2021248090A1 · 2021 [cited by applicant]
WO 2021248095A1 · 2021 [cited by applicant]
WO 2021249563A1 · 2021 [cited by applicant]
WO 2021252339A1 · 2021 [cited by applicant]
WO 2021257828A1 · 2021 [cited by applicant]
WO 2021259331A1 · 2021 [cited by applicant]
WO 2022002102A1 · 2022 [cited by applicant]
WO 2022015375A1 · 2022 [cited by applicant]
WO 2022017339A1 · 2022 [cited by applicant]
WO 2022028346A1 · 2022 [cited by applicant]
WO 2022028492A1 · 2022 [cited by applicant]
WO 2022031678A1 · 2022 [cited by applicant]
WO 2022036176A1 · 2022 [cited by applicant]
T.R. Golub. Molecular Classification of Cancer . . . SCIENCE vol. 286 Oct. 15, 1999. p. 531-38. (Year: 1999). [cited by examiner]
Gridelli et al. The Potential Role of mTOR Inhibitors . . . , The Oncologist, 2008, p. 139-147 (Year: 2008). [cited by examiner]
Brown et al. Bioisosteres in Medicinal Chemistry—Classical Bioisosteres, Wiley-VCH Verlag Gmbh & Co. KGaA, 2012, p. 15-29 (Year: 2012). [cited by examiner]
Molina-Arcas et al. Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, vol. 3, Supplement 2, p. A7, Jun. 30-Jul. 3, 2018 (Year: 2018). [cited by examiner]
International Search Report and Written Opinion for PCT Application No. PCT/US2019/050240 mailed Jan. 29, 2020. [cited by applicant]
Blake et al., “Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2” Bioorganic & Medicinal Chemistry Letters, Jun. 15, 2014, vol. 24, p. 2635-2639; p. 2635, Figure 1, p. 2637, right col, Para 2. [cited by applicant]
Ambrogio, C. et al., “Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma”, Nature Medicine, vol. 22, No. 3, pp. 270-279, Mar. 2016. [cited by applicant]
Araki, M. et al., “Solution Structure of the State 1 Conformer of GTP-bound H-Ras Protein and Distinct Dynamic Properties between the State 1 and State 2 Conformers” The Journal of Biological Chemistry vol. 286, No. 45,… [cited by applicant]
Broutin, S. et al., “Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer”, British Journal of Cancer (2016), 1-4 | doi: 10.1038/bjc.2016.220. [cited by applicant]
Burgess, M. et al., “KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer”, Cell 168, 817-829, Feb. 23, 2017, Elsevier Inc. [cited by applicant]
Cammarata, M. et al., “Impact of G12 Mutations on the Structure of K-Ras Probed by Ultraviolet Photodissociation Mass Spectrometry”, . Am. Chem. Soc., 2016, 138 (40), pp. 13187-13196. [cited by applicant]
Costa-Cabral, S. et al., “CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours”, PLOS ONE | DOI: 10.1371/journal.pone.0149099 Feb. 16, 2016. [cited by applicant]
Cully, “Closing the door on KRAS-mutant lung cancer”, Nature Reviews Drug Discovery | Published online Nov. 3, 2016; doi:10.1038/nrd.2016.216, MacMillan Publishers. [cited by applicant]
Dharmaiah, S. et al., “Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ”, E6766-E6775, PNAS, Published online Oct. 17, 2016. [cited by applicant]
Fiala, O. et al., “The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in nonesmall cell lung cancer”, Cancer Ge… [cited by applicant]
Ford, B. et al., “Structure of the G60A Mutant of Ras Implications for the Dominant Negative Effect”, J. Biol. Chem., vol. 280, No. 27, Issue of Jul. 8, pp. 25697-25705, 2005. [cited by applicant]
Hall, B. et al., “The structural basis for the transition from Ras-GTP to Ras-GDP”, PNAS, vol. 99, No. 19, pp. 12138-12142, Sep. 17, 2002. [cited by applicant]
Hunter, J. et al., “In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C”, PNAS, vol. 111, No. 24, pp. 8895-8900, Jun. 17, 2014. [cited by applicant]
Ihle, N. et al., “Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome”, JNCI, Oxford Journals, vol. 104, Issue 3, Feb. 8, 2012. [cited by applicant]
Jarvis, L., “Have drug hunters finally cracked KRas?”, c&en, vol. 94, Issue 23, pp. 28-33, Jun. 6, 2016. [cited by applicant]
Kamerkar, S. et al., “Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer”, Nature 546, 498-503 (Jun. 22, 2017) doi:10.1038/nature22341. [cited by applicant]
Kaufman, J. et al., “Treatment of KRAS-Mutant Non-Small Cell Lung Cancer The End of the Beginning for Targeted Therapies”, JAMA May 9, 2017 vol. 317, No. 18. [cited by applicant]
Kerr, E. et al., “Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities”, Nature 531, 110-113, (Mar. 3, 2016) doi:10.1038/nature16967. [cited by applicant]
Kim, J. et al., “CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells”, Nature 546, 168-172, (Jun. 1, 2017) doi:10.1038/nature22359. [cited by applicant]
Kim, J. et al., “XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer”, Nature 538, 114-117 (Oct. 6, 2016) doi:10.1038/nature19771. [cited by applicant]
Kitai, H. et al., “Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer”, SSN: 2154-1248 (Print) 2154-1256 (Online) Journal homepage: http://www.tandfonline.com/loi/ksgt20. [cited by applicant]
Kosloff, M. et al., “GTPase Catalysis by Ras and Other G-proteins: Insights from Substrate Directed SuperImposition”, J. Mol. Biol. (2003) 331, 1157-1170, doi:10.1016/S0022-2836(03)00847-7. [cited by applicant]
Ledford, H., “Thirty years of pursuit have failed to yield a drug to take on one of the deadliest families of cancer-causing proteins. Now some researchers are taking another shot.” The RAS Renaissance, Nature, vol. 520… [cited by applicant]
Lim, S. et all., “Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor”, Angew. Chem. Int. Ed. 2014, 53, 199-204. [cited by applicant]
Loncle, C. et al., “The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes KrasG12D-mediated pancreatic cancer initiation”, Cell Death and Disease (2016) 7, e2295; doi:10.1038/cddis.2… [cited by applicant]
Manchado, E. et al., “A combinatorial strategy for treating KRAS-mutant lung cancer”, Nature 534, 647-651 (Jun. 30, 2016) doi:10.1038/nature18600. [cited by applicant]
Maurer, T. et al., “Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity”, PNAS, Apr. 3, 2012, vol. 109, No. 14, pp. 5299-5304. [cited by applicant]
Muller, M. et al., “Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity”, Scientific Reports, 7: 3687 | DOI:10.1038/s41598-017-03973-6. [cited by applicant]
Nadal, E. et al., “Abstract C141: Kras G12C mutation is prognostic of poor outcome in resected lung adenocarcinomas and predictive of poor response to MEK inhibition in vitro”, Mol Cancer Ther Nov. 2013 12; C141, doi: 1… [cited by applicant]
Nussinov, R. et al., “Independent and core pathways in oncogenic KRAS signaling”, Journal: Expert Review of Proteomics, DOI: 10.1080/14789450.2016.1209417, Published by Taylor & Francis. [cited by applicant]
Ostrem, J. et al., “Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design”, Nature Reviews Drug Discovery 15, 771-785 (2016) doi:10.1038/nrd.2016.139. [cited by applicant]
Ostrem, J. et al., “K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions”, Nature, vol. 503: 548, Nov. 28, 2013. [cited by applicant]
Papke, B. et al., “Drugging RAS: Know the enemy”, Science 355, 1158-1163 (2017) Mar. 17, 2017. [cited by applicant]
Park, K. et al., “The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib”, Cancer Letters 372 (2016) 75-81. [cited by applicant]
Patricelli, M. et al., “Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State”, OnlineFirst on Jan. 6, 2016; DOI: 10.1158/2159-8290.CD-15-1105. [cited by applicant]
Perara, D. et al., “Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents”, Scientific Reports, 6:29741, DOI: 10.1038/srep29741. [cited by applicant]
Renaud, S. et al., “KRAS in Non-Small-Cell Lung Cancer: Oncogenic Addiction and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors”, JAMA Oncology Published online Jul. 21, 2016. [cited by applicant]
Riquelme, E. et al., “Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations”, Author Manuscript Published OnlineFirst on Dec. 16, 2015; DOI: 10.11… [cited by applicant]
Ross, S. et al., “Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS”, Sci. Transl. Med. 9, eaal5253 (2017) Jun. 14, 2017. [cited by applicant]
Rudoni, S. et al., “Role of guanine nucleotides in the regulation of the Ras/cAMP pathway in [cited by applicant]
Samatar, A. et al., “Targeting Ras-Erk signalling in cancer: promises and challenges”, Nature Reviews Drug Discovery, vol. 13, pp. 928-942, Dec. 2014. [cited by applicant]
Sautier, B. et al., “Latest advances towards Ras inhibition—A medicinal chemistry perspective”, Angewandte Chemie International Edition, 10.1002/anie.201608270. [cited by applicant]
Serresi, M. et al., “Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer”, Cancer Cell 29, 17-31, Jan. 11, 2016, 2016 Elsevier Inc. … [cited by applicant]
Shima, F. et al., “Structural Basis for Conformational Dynamics of GTP-bound Ras Protein”, The Journal of Biological Chemistry, vol. 285, No. 29, pp. 22696-22705, Jul. 16, 2010. [cited by applicant]
Shipman, L., “Putting the brakes on KRAS-G12C nucleotide cycling”, Nature Reviews Cancer, Published online Feb. 19, 2016; doi:10.1038/nrc.2016.13. [cited by applicant]
Spoerner, M. et al., “Dynamic properties of the Ras switch I region and its importance for binding to effectors”, PNAS, vol. 98, No. 9, pp. 4944-4949, Apr. 24, 2001. [cited by applicant]
Sun, Q. et al., “Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation**”, Angew. Chem. Int. Ed. 2012, 51, 1-5, 2012 Wiley-VCH Verlag Gmbh & Co. KGaA, Weinheim. [cited by applicant]
Sun, Q., et al., “A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand”, J Biomol NMR (2014) 60:11-14 DOI 10.1007/s10858-014-9849-8. [cited by applicant]
Sunaga, N. et al., “Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer”, Oncogene (2013) 32, 4034-4042& 2013 Macmilla… [cited by applicant]
Sung, Y. et al., “Mutagenesis of the H-ras p21 at Glycine-60 Residue Disrupts GTP-Induced Conformational Change”, Biochemistry 1995, 34, 3470-3477, American Chemical Society. [cited by applicant]
Tape, C. et al., “Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation”, Cell 165, 1-11May 5, 2016. [cited by applicant]
Thierry, A. et al., “Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA”, Nature Medicine, vol. 20, No. 4, pp. 430-436 , Apr. 2014. [cited by applicant]
Tran, E. et al., “T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer”, N Engl J Med 2016;375:2255-62., Dec. 8, 2016; DOI: 10.1056/NEJMoa1609279. [cited by applicant]
Wang, Y. et al., “Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators”, J. Med. Chem. 2013, 56, 5219-5230, dx.doi.org/10.1021/jm3017706; 2013 American Chemical Society, ACS Pub… [cited by applicant]
Wang, Y. et al., “Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma”, International Journal of Biological Sciences 2017; 13(5): 652-659. doi: 10.7150/ijbs.19108. [cited by applicant]
Welsch, M. et al., “Multivalent Small-Molecule Pan-RAS Inhibitors”, Welsch et al., 2017, Cell 168, 878-889 Feb. 23, 2017; 2017 Elsevier Inc. http://dx.doi.org/10.1016/j.cell.2017.02.006. [cited by applicant]
Winter, J. et al., “Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation”, J. Med. Chem. 2015, 58, 2265-2274; DOI: 10.1021/jm501660t; 2015 American Chemical Society, ACS … [cited by applicant]
Wood, K. et al., “Reply” Comments & Response, Letters JAMA Oncology Published online Jul. 21, 2016, American Medical Association. [cited by applicant]
Xiong, Y. et al., “Development of covalent guanosine mimetic inhibitors of G12C KRAS”, ACS Med. Chem. Lett., Just Accepted Manuscript ⋅ DOI: 10.1021/acsmedchemlett.6b00373 ⋅ Publication Date (Web): Nov. 30, 2016 Downloa… [cited by applicant]
Xiong, Y. et al., “Covalent Guanosine Mimetic Inhibitors of G12C KRAS” ACS Med. Chem. Lett. 2017, 8, 61-66, DOI: 10.1021/acsmedchemlett 6b00373; 2016 American Chemical Society, ACS Publications. [cited by applicant]
Janes et al., “Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor”, Cell 172, 578-589, Jan. 25, 2018. [cited by applicant]
Singh et al., “A Gene Expression Signature Associated with K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival, Cancer Cell 15, p. 489-500, Jun. 2, 2009. [cited by applicant]
Stephen et al., “Dragging Ras Back in the Ring”, Cancer Cell 25, p. 272, Mar. 17, 2014. [cited by applicant]
Zhu et al., “Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit”, doi:10.1158/2159-8290.CD-13-0646; Cancer Discovery Published OnlineFirst Jan. 20, 2014. [cited by applicant]
Simanshu et al., “RAS Proteins and Their Regulators in Human Disease”, Cell 170, p. 17, Jun. 29, 2017. [cited by applicant]
Pacold et al., “Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase gamma”, Cell, vol. 103, p. 931-943, Dec. 8, 2000. [cited by applicant]
Lech-Gustav et al., “The Renaissance of Ras”, ACS Chem. Biol., 2014, 9, 2447-2458. [cited by applicant]
Karachaliou et al., “KRAS Mutations in Lung Cancer”, Clinical Lung Cancer, vol. 14, No. 3, p. 2015-14, 2013. [cited by applicant]
Schwartz et al., “Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance”, PNAS, vol. 111, No. 1, p. 173-178, Jan. 7, 2014. [cited by applicant]
Sun et al., “A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand”, J. Biomol. NMR (2014) vol. 60 p. 11-14. [cited by applicant]
Kyriakis, J., “Thinking Outside the Box about Ras”, J. Biol. Chem. 2009, 284:10993-10994, published online Dec. 17, 2008. [cited by applicant]
Sunaga et al., “Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy”, Mol. Cancer Ther. 2011; 10:336-346. [cited by applicant]
Serafimova et al., “Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles”, Nat Chem Biol.; 8(5):471-476. doi:10.1038/nchembio.925. [cited by applicant]
Walker et al., “Structural insights into phosphoinositide 3-kinase catalysis and signalling”, Nature vol. 402, p. 18 Nov. 1999; www.nature.com. [cited by applicant]
Barbie et al., “Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1”, Nature, vol. 462, p. 108, Nov. 5, 2009; doi:10.1038/nature08460. [cited by applicant]
Zimmermann et al., “Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling”, Nature, vol. 497, p. 638, May 30, 2013. [cited by applicant]
Karnoub et al., “Ras oncogenes: split personalities”, Nature Reviews, molecular Cell Biology, vol. 9, Jul. 2008 p. 517. [cited by applicant]
Nassar et al., “Ras/Rap effector specificity determined by charge reversal”, Nature Structural Biology, vol. 3, No. 8, Aug. 1996. [cited by applicant]
De Rooij et al., “Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras”, Oncogene (1997) 14, 623-625, 1997 Stockton Press. [cited by applicant]
Cox et al., “The dark side of RAs: regulation of apoptosis”, Oncogene (2003) 22, 8999-9006, 2003 Nature Publishing Group. [cited by applicant]
Tanaka et al., “Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth”, Oncogene (2010) 29, 6064-6070, 2010 Macmillan Publishers Limite… [cited by applicant]
Grant et al., “Novel Allosteric Sites on Ras for Lead Generation”, PLOS ONE, vol. 6, Issue 10, Oct. 2011. [cited by applicant]
Maegley et al., “Ras-catalyzed hydrolysis of GTP: A new perspective from model studies”, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 8160-8166, Aug. 1996. [cited by applicant]
Ahmadian et al., “Guanosine triphosphatase stimulation of oncogenic Ras mutants”, Proc. Natl. Acad. Sci. USA, vol. 96, pp. 7065-7070, Jun. 1999. [cited by applicant]
Kiel et al., “Electrostatically optimized Ras-binding Ral guanine dissociation stimulator mutants increase the rate of association by stabilizing the encounter complex”, PNAS, vol. 101, No. 25, p. 9223-9228, Jun. 22, 20… [cited by applicant]
Kotting et al., “The GAP arginine finger movement into the catalytic site of Ras increases the activation entropy”, PNAS, vol. 105, No. 17, p. 6260-6265, Apr. 29, 2008. [cited by applicant]
Shaw et al., “Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress”, PNAS, vol. 108, No. 21, p. 8773-8778, May 24, 2011. [cited by applicant]
Ischenko et al., “Direct reprogramming by oncogenic Ras and Myc”, PNAS early edition 1, 2013. [cited by applicant]
Smith et al., “NMR-based functional profiling of RASopathies and oncogenic RAS mutations”, PNAS, vol. 110, No. 12, p. 4574-4579, Mar. 19, 2013. [cited by applicant]
Shima, et al., “In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction”, PNAS, vol. 110, No. 20, p. 8182-8187, May 14, 2013. [cited by applicant]
Burns et al., “Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange”, PNAS, vol. 111, No. 9, p. 3401-3406, Mar. 4, 2014. [cited by applicant]
Zeng et al., “Design of inhibitors of Ras-Raf interaction using a computational combinatorial algorithm”, Protein Engineering, vol. 14, No. 1, p. 39-45, 2001. [cited by applicant]
Scheffzek et al., “The Ras-RasGAP Complex: Structural Basis for GTPAse Activation and Its Loss in Oncogenic Ras Mutants”, Science, vol. 277, Jul. 18, 1997. [cited by applicant]
Taylor et al., “Protein Kinases: Evolution of Synamic Regulatory Proteins”, Trends Biochem Sci. Feb. 2011; 36 (2): 65-77. doi:10.1016/j.tibs.2010.09.006. [cited by applicant]
Fell et al. ‘Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity’, ACS Medicinal Chemistry Letters, Nov. 7, 2018 (Nov. 7, 2018), vol. 9, pp. 1230-1234. [cited by applicant]
International Search Report and Written Opinion for corresponding PCT application No. PCT/US18/61060 mailed Feb. 7, 2019. [cited by applicant]
Martin, James S. et al., “Characterising covalent warhead reactivity”, Bioorganic & Medicinal Chemistry, 27 (2019) 2066-2074. [cited by applicant]
Palkowitz, Maximilian D. et al., “Synthesis of Diverse N-Acryloyl Azetidines and Evaluation of Their Enhanced Thiol Reactivities”, ACS Publications Mar. 16, 2017, 9, 9, 2270-2273. [cited by applicant]
Figueras, A. et al., “The impact of KRAS mutations on VEGF-A production and tumour vascular network”, BMC Cancer 2013, 13:125. [cited by applicant]
Janes, M. et al., “Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor”, 2018, Cell 172, 578-589, Jan. 25, 2018, Elsevier Inc. [cited by applicant]
Matikas, A. et al., “Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity”, Cretical Reviews in Oncology/Hematology 110 (2017) 1-12, Elsevier Ireland Ltd. [cited by applicant]
McCormick, F., “Targeting KRAS Directly”, Annual Review of Cancer Biology, 2018, 2:81, 81-90. [cited by applicant]
Misalee, S. et al., KRAS G12C Nsclc models are sensitive to direct targeting of KRAS in combination with PI3K Inhibition, Downloaded from clincancerres.aacrjournals.org on Oct. 22, 2018. © 2018 American Association for … [cited by applicant]
Nabet, B. et al., “It Takes Two To Target: A Study in KRAS Dimerization”, pubs.acs.org/biochemistry, DOI: 10.1021. [cited by applicant]
O'Bryan, J., “Pharmacological Targeting of RAS: Recent Success with Direct Inhibitors”, Pharmacological Research (2018), https://doi.org/10.1016/j.phrs.2018.10.021. [cited by applicant]
Ruess, D. et al., “Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase”, Nature Medicine, Letters, https://doi.org/10.1038/s41591-018-0024-8. [cited by applicant]
Simanshu, D. et al., “RAS Proteins and Their Regulators in Human Disease”, Cell 170, 17-33, Jun. 29, 2017. [cited by applicant]
Suzawa, K., et al., “Activation of KRAS mediates resistance to targeted therapy in MET exon 14 mutant non-small cell lung cancer”, Author Manuscript Published OnlineFirst on Oct. 23, 2018; DOI: 10.1158/1078-0432.CCR-18-… [cited by applicant]
Wijeratne, A. et al., “Chemical Proteomic Characterization of a covalent KRASG12C inhibitor”, ACS Med. Chem. Ltter., DOI: 10.1021/acsmedchemlett.8b00110, May 21, 2018. [cited by applicant]
Wood, K. et al., “Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer A Review”, JAMA Oncol. 2016:2(6), 805-812, Apr. 21, 2016. [cited by applicant]
Yen, I. et al., “Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors”, Cancer Cell 34, 611-625, Oct. 8, 2018, Elsevier Inc. [cited by applicant]
Ziemke, E. et al., “Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6”, Clin Cancer Res; 22(2) Jan. 15, 2016. [cited by applicant]
Ambrogio, C. et al., “KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS”, Cell 172, 1-12, Feb. 8, 2018, Elsevier Inc. [cited by applicant]
Hansen, R. et al., “An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors”, Scientific Reports, 8:14312 (2018), DOI: 10.1038/s41598-018-32683-w. [cited by applicant]
Pantar, T. et al., “Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling”, PLOS Computational Biology, Sep. 10,… [cited by applicant]
Skoulidis, F. et al., “STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma”, Downloaded from cancerdiscovery.aacrjournals.org on May 21, 2018. © 2018 American Association for Cancer Res… [cited by applicant]
Yuan, T. et al., “Differential Effector Engagement by Oncogenic KRAS”, Cell Reports 22, 1889-1902, Feb. 13, 2018, Cell Press. [cited by applicant]
Calles, et al., “Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma”, Clin Cancer Res. 2015. 21(12). [cited by applicant]
Torralvo et al., “The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience”, Cancer Genomics & Proteomics, 2019. 16: 577-582. [cited by applicant]
Supplementary European Search Report for corresponding Application No. EP 19 85 9200 mailed Jun. 1, 2022. [cited by applicant]
Molina-Arcas M. et al: “15 Identification of new combination therapies for lung cancer tumours harbouring KRAS mutations”, ESMO Open: Cancer Horizons, vol. 3, Jun. 1, 2018, p. A7. [cited by applicant]
Lito, P. et al.: “Allele-specific inhibitors inactivate mutant Kras G12C by a trapping mechanism”, Science, vol. 351(6273), pp. 604-608 (2016). [cited by applicant]
Coma Silvia et al: “Synergistic combinations with the novel dual RAF/MEK inhibitor VS-6766: Establishing VS-6766 as the backbone of therapy for RAS-driven cancers”, RAS-Targeted Drug Discovery, Feb. 23, 2021 (Feb. 23, 2… [cited by applicant]
Hallin Jill et al: “Data from The KRAS supG12C /supInhibitor MRTX849Provides Insight toward Therapeutic Susceptibility of KRAS-MutantCancers in Mouse Models and Patients”, Cancer Discovery, Jan. 1, 2020 (Jan. 1, 2020), … [cited by applicant]
Hallin, J. et al. “The KRAS612c Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients” Cancer Discovery vol. 10(1) pp. 54-71 (2020). [cited by applicant]